TEARDRoP Oncology: Good practices for paediatric biobanking

With the support of the Olivia Hendrickx Research Fund, the ‘Team EARly DRug development in Paediatric oncology (TEARDRoP)’ consortium was founded to support the translation of new research findings in the field of pediatric oncology to new therapeutic options, making science find its way to children in need of new and better treatments. In specific, the consortium aims to support biobanking efforts through a bottom-up approach by: (i) bringing in to (clinical) practice practical flows for the biobanking of human body material for (inter)national academic clinical studies and general research, embedded into routine in order to help healthcare workers, (ii) set-up a national pediatric oncological-specific biobank collection as these are rare and precious materials The longitudinal collection and access to patient material via this biobanking effort is crucial for the translation of (basic) research findings to the clinic, and is of utmost importance for the development and selection of the best fit treatment for each patient, the focus of personalized medicine. To ensure all (Belgian) patients benefit from the initiative, the TEARDRoP consortium has a close partnership with the ‘Belgian Society of Pediatric Haematology Oncology (BSPHO)’, an organization that has been supporting academic research into children’s cancer for years

TEARDRoP Oncology: BBRMI.be workshop on sustainability

With the support of the Olivia Hendrickx Research Fund, the ‘Team EARly DRug development in Paediatric oncology (TEARDRoP)’ consortium was founded. As the name indicates, this consortium was set up to support the translation of new research findings in the field of paediatric oncology to new therapeutic options, making science find its way to children in need of new and better treatments. In specific, the consortium will help bridge the gap between basic and clinical research through stimulating close collaborations and supporting biobanking efforts. Therefor I write and bring in to (clinical) practice practical flows for the biobanking of human body material for (inter)national academic clinical studies and general research, as well as support the set-up of a national pediatric-specific biobank collection. The access to patient material via this biobanking effort is crucial for the translation of (basic) research findings to the clinic, and is of utmost importance for the development and selection of the best fit treatment for each patient, the focus of personalized medicine. Thanks to the support of the Olivia Fund, I was appointed as coordinator of this consortium, under the direct supervision of paediatric oncologist Prof. Dr. Bram De Wilde (UZ Gent, CRIG), Prof. Dr. Catherine Van Der Straeten (HIRUZ UZ Gent), and Prof. Dr. Tim Lammens (UGent, CRIG). To ensure all (Belgian) patients benefit from the initiative, the TEARDRoP consortium has a close partnership with the ‘Belgian Society of Pediatric Haematology Oncology (BSPHO)’, an organization that has been supporting academic research into children’s cancer for years

The TEARDRoP (Team early drug development in Paediatric oncology) consortium : to help Research find its way to improved treatments for children with cancer

Liselot Mus THE TEARDRoP (Team EARly DRug development in Paediatric oncology) CONSORTIUM: TO HELP RESEARCH FIND ITS WAY TO IMPROVED TREATMENTS FOR CHILDREN WITH CANCER With the support of the Olivia Hendrickx Research Fund, the ‘Team EARly DRug development in Paediatric oncology (TEARDRoP)’ consortium was founded. As the name indicates, this consortium was set up to support the translation of new research findings in the field of paediatric oncology to new therapeutic options, making science find its way to children in need of new and better treatments. In specific, the consortium will help bridge the gap between basic and clinical research through stimulating close collaborations and supporting biobanking efforts. The access to patient material via this biobanking effort is crucial for the translation of (basic) research findings to the clinic, and is of utmost importance for the development and selection of the best fit treatment for each patient, the focus of personalized medicine. Thanks to the support of the Olivia Fund, former CRIG researcher Dr. Ir. Liselot Mus could be appointed as coordinator of this consortium, under the direct supervision of paediatric oncologist Prof. Dr. Bram De Wilde (UZ Gent, CRIG) and of Prof. Dr. Catherine Van Der Straeten, head of the ‘Health, innovation and research institute (HIRUZ)’ of UZ Gent. To ensure all (Belgian) patients benefit from the initiative, the TEARDRoP consortium has a close partnership with the ‘Belgian Society of Pediatric Haematology Oncology (BSPHO)’, an organization that has been supporting academic research into children’s cancer for years. On the 28th of June 2021, the consortium was officially launched by Mrs. Ilse De Reze (chair of the Olivia Fund), Prof. Dr. Bram De Wilde and Dr. Ir. Liselot Mus. As several CRIG teams work on paediatric oncology and are therefore directly involved in the ‘TEARDRoP’ consortium, this initiative is also a strong boost for our CRIG research